Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:GLSI NASDAQ:QTTB NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$3.22+3.2%$3.72$2.61▼$13.99$289.14M1.24904,956 shs733,391 shsGLSIGreenwich LifeSciences$22.86-3.2%$25.07$7.78▼$34.10$327.24M1.39125,671 shs74,619 shsQTTBQ32 Bio$5.37-1.3%$5.90$1.35▼$8.05$92.24M-0.05322,560 shs115,929 shsRZLTRezolute$3.21+3.9%$3.14$1.07▼$11.46$295.71M0.661.47 million shs710,344 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences0.00%-6.59%+2.63%-23.90%-63.10%GLSIGreenwich LifeSciences0.00%0.00%-2.40%-18.55%+154.25%QTTBQ32 Bio0.00%-3.20%-0.90%+27.85%+245.29%RZLTRezolute0.00%-3.44%-13.20%-0.96%-14.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$3.22+3.2%$3.72$2.61▼$13.99$289.14M1.24904,956 shs733,391 shsGLSIGreenwich LifeSciences$22.86-3.2%$25.07$7.78▼$34.10$327.24M1.39125,671 shs74,619 shsQTTBQ32 Bio$5.37-1.3%$5.90$1.35▼$8.05$92.24M-0.05322,560 shs115,929 shsRZLTRezolute$3.21+3.9%$3.14$1.07▼$11.46$295.71M0.661.47 million shs710,344 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences0.00%-6.59%+2.63%-23.90%-63.10%GLSIGreenwich LifeSciences0.00%0.00%-2.40%-18.55%+154.25%QTTBQ32 Bio0.00%-3.20%-0.90%+27.85%+245.29%RZLTRezolute0.00%-3.44%-13.20%-0.96%-14.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 2.40Hold$21.33562.53% UpsideGLSIGreenwich LifeSciences 2.33Hold$47.50107.79% UpsideQTTBQ32 Bio 2.67Moderate Buy$13.00142.09% UpsideRZLTRezolute 2.45Hold$8.00149.22% UpsideCurrent Analyst Ratings BreakdownLatest QTTB, RZLT, AVXL, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.005/4/2026AVXLAnavex Life Sciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.004/22/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026RZLTRezolute Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026AVXLAnavex Life Sciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.003/25/2026RZLTRezolute WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.00 ➝ $5.003/23/2026AVXLAnavex Life Sciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.003/12/2026QTTBQ32 Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/10/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.002/25/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.002/10/2026AVXLAnavex Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.10 per shareN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AQTTBQ32 Bio$53.74M1.69$1.50 per share3.59$2.73 per share1.97RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%5/12/2026 (Estimated)GLSIGreenwich LifeSciences-$15.79M-$1.46N/AN/AN/AN/A-1,042.84%-565.43%5/19/2026 (Estimated)QTTBQ32 Bio$29.82M$2.662.02N/AN/AN/A149.23%34.50%N/ARZLTRezolute-$74.41M-$0.93N/AN/AN/AN/A-64.81%-59.37%5/12/2026 (Estimated)Latest QTTB, RZLT, AVXL, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026N/AGLSIGreenwich LifeSciences-$0.33N/AN/AN/AN/AN/A5/12/2026Q2 2026AVXLAnavex Life Sciences-$0.07N/AN/AN/AN/AN/A5/12/2026Q3 2026RZLTRezolute-$0.1686N/AN/AN/AN/AN/A5/5/2026Q1 2026QTTBQ32 Bio-$0.68-$0.54+$0.14-$0.54$39.74 millionN/A3/10/2026Q4 2025QTTBQ32 Bio-$1.06$3.65+$4.71$4.58N/A$53.74 million2/12/2026Q2 2026RZLTRezolute-$0.16-$0.22-$0.06-$0.22N/AN/A2/9/2026Q1 2026AVXLAnavex Life Sciences-$0.10-$0.06+$0.04-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A20.8720.87GLSIGreenwich LifeSciencesN/A2.352.35QTTBQ32 Bio0.045.364.85RZLTRezoluteN/A14.1814.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%GLSIGreenwich LifeSciences4.16%QTTBQ32 Bio31.32%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%GLSIGreenwich LifeSciences51.47%QTTBQ32 Bio40.00%RZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4092.67 million82.11 millionOptionableGLSIGreenwich LifeSciences313.85 million6.72 millionNot OptionableQTTBQ32 Bio3916.96 million10.17 millionN/ARZLTRezolute4095.70 million81.55 millionOptionableQTTB, RZLT, AVXL, and GLSI HeadlinesRecent News About These CompaniesRezolute (RZLT) to Release Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society ...May 1, 2026 | markets.businessinsider.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingMay 1, 2026 | globenewswire.comRezolute, Inc. Investigated by the Portnoy Law FirmApril 24, 2026 | globenewswire.comRezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual MeetingApril 21, 2026 | globenewswire.comRezolute, Inc. (NASDAQ:RZLT) Short Interest Down 21.2% in MarchApril 16, 2026 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Hold" by BrokeragesApril 16, 2026 | marketbeat.comRezolute: Sell Rating Despite FDA Feedback From Type B Meeting For ErsodetugMarch 30, 2026 | seekingalpha.comWedbush upgrades Rezolute (RZLT)March 26, 2026 | msn.comRezolute Stock Gains After FDA Meeting on Ersodetug Program UpdateMarch 25, 2026 | zacks.comFDA Review Puts Rezolute's Genetic Disorder Drug Path In QuestionMarch 24, 2026 | benzinga.comRezolute gains after positive FDA meeting over lead assetMarch 24, 2026 | msn.comRezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA MeetingMarch 24, 2026 | globenewswire.comRZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into RezoluteMarch 6, 2026 | businesswire.comINVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)March 5, 2026 | prnewswire.comRezolute to Participate in the Citizens Life Sciences ConferenceMarch 4, 2026 | globenewswire.comRZLT SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteMarch 3, 2026 | globenewswire.comRZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteFebruary 28, 2026 | prnewswire.comINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteFebruary 26, 2026 | globenewswire.comRZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteFebruary 24, 2026 | newsfilecorp.comNSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteFebruary 21, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTTB, RZLT, AVXL, and GLSI Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$3.22 +0.10 (+3.21%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.28 +0.05 (+1.71%) As of 05/8/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Greenwich LifeSciences NASDAQ:GLSI$22.86 -0.76 (-3.22%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$22.90 +0.05 (+0.20%) As of 05/8/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Q32 Bio NASDAQ:QTTB$5.37 -0.07 (-1.29%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$5.36 -0.01 (-0.28%) As of 05/8/2026 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Rezolute NASDAQ:RZLT$3.21 +0.12 (+3.88%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.16 -0.06 (-1.71%) As of 05/8/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
